

## Preterm Prevention Clinic Treatment Pathway

This guidance does not override the individual responsibility of health professionals to make appropriate decision according to the circumstances of the individual patient in consultation with the patient and /or carer. Health care professionals must be prepared to justify any deviation from this guidance.

### Introduction

Overview of the criteria and process for referral into Preterm Prevention clinic

### This guideline is for use by the following staff groups:

Community Midwives, clinic midwives and obstetric doctors.

### Lead Clinician(s)

Claire Davis Catherine Hillman Cooper	Preterm Prevention Midwife Consultant Obstetrician (Preterm Lead)
--	--

Approved by *Maternity Governance Meeting* on: 22<sup>nd</sup> May 2026

Approved by Medicines Safety Committee on: N/A

Review Date: 22<sup>nd</sup> May 2029

This is the most current document and should be used until a revised version is in place

### Key amendments to this guideline

Date	Amendment	Approved by:
January 2020	New Document	Maternity Governance
February 2023	Reviewed	Maternity Governance
4 <sup>th</sup> June 2024	Document extended for another 12 months whilst under review	Maternity Governance
June 2024	Reviewed – minor amendments	Maternity Governance
May 2026	Reviewed – removal off fFN, Bicornuate uterus now to be seen at 16 weeks, Ashermans syndrome added to high risk and Multiple pregnancy Referral added.	Maternity Governance

## Contents

Background .....	3
Prediction of Preterm delivery .....	4
Cervical sonography .....	4
Interventions for the prevention of preterm birth .....	4
Cervical cerclage.....	4
Emergency cerclage .....	4
Evidence.....	5
Progesterone.....	5
Aspirin .....	6
Arabin Pessary.....	6
Arabin Pessary.....	7
Preterm Prevention Clinic (PPC) .....	7
Protocol for referral to Preterm Prevention Clinic .....	8
General principles .....	9
QuIPP .....	10
How to counsel .....	11
References .....	12

## **Background**

Every year worldwide approximately 13 million premature deliveries babies are born premature, with a global incidence of up to 12%. Preterm birth is defined as birth before 37 weeks' gestation. It is a major contributor to neonatal and infant morbidity and mortality<sup>1</sup>. Spontaneous preterm birth accounts for about three-quarters of these births and births before 30 weeks of gestation account for most neonatal deaths<sup>2</sup>. The costs of preterm labour are significant, costing the US economy 26.2 billion dollars in 2005. The rate of spontaneous preterm birth in 2017 at Worcestershire Acute Hospitals Trust was around 9%. Preterm birth also has marked psychological, physical and emotional sequelae for those families affected<sup>3</sup>.

The incidence of spontaneous preterm birth is continuing to rise. The reasons driving this increase remain unclear<sup>4</sup>. There are certain clinical measures employed that aim to prevent preterm labour. Current interventions could potentially eliminate up to 50% of recurrent preterm births<sup>4</sup>. Management needs to target those women at greatest risk of preterm delivery to improve care and ultimately outcome for both mother and baby. Interventions such as cervical cerclage, pre-delivery steroids for fetal lung maturation, progesterone, antibiotics, magnesium sulphate, tocolytics and timely in-utero transfer may form part of a broader package of care offered to women demonstrated to be at greatest risk of early delivery.

Women with a history of a previous preterm labour or a second trimester loss are at high risk of having a further preterm delivery<sup>5</sup>. Other risk factors include previous cervical surgery, terminations of pregnancy, repeated dilatation and curettage and trachelectomy<sup>6</sup> and caesarean at full dilatation. There are many other "softer" risk factors implicated in the pathogenesis of preterm labour. These include age, parity, body mass index, ethnicity, socio-economic status, smoking, anxiety and depression also associated with premature labour<sup>5</sup>. The most challenging element of this clinical conundrum is that preterm delivery is a multifactorial problem, with multiple aetiologies. More recently, the "Saving Babies lives Bundle version 3" has reiterated the importance of reducing preterm birth and through its 5<sup>th</sup> element made it a requirement to formalize the risk assessment and management of women at risk. As part of this, the prediction of women at greatest risk is of paramount importance. Interventions to reduce risk can then be implemented.

## **Prediction of Preterm delivery**

### **Cervical sonography**

The cervix provides mechanical strength and helps to prevent ascending infection from the vagina penetrating the intra-uterine space. Cervical insufficiency, categorized as painless cervical dilatation, is the inability of the uterine cervix to retain a pregnancy in the absence of contractions or labour. Transvaginal ultrasound is the gold standard for assessment of cervical length. It has been reliably shown that the shorter the sonographic cervical length in the mid-trimester, the higher the risk of spontaneous preterm labour, presumably due to an “insufficient cervix”

There is no consensus as to what constitutes a sonographically short cervix. Some studies use a cervical length of <25mm, whilst others reduce this further to <15mm. Despite this clinical conflict, a shortening cervix remains the single most powerful predictor for preterm birth in the index pregnancy. Furthermore, a shortening cervix is far more informative than a history of previous preterm birth. With shortening of the cervix to <15 mm, there is almost

a 50% risk of preterm birth at 32 weeks<sup>7</sup>. Therefore, through cervical length screening, interventions should be offered to those women at greatest risk in a timely fashion<sup>8</sup>.

Nevertheless, the use of cervical length scanning as a risk assessment tool has its limitations when used in isolation. Previous studies by Romero et al. indicate that only 8% of all patients with a mid-trimester cervical length  $\leq 15\text{mm}$ <sup>9</sup> deliver preterm at <32 weeks' gestation.

### **Interventions for the prevention of preterm birth**

Interventions available at Worcester Royal for the prevention of preterm birth include:

- Cervical Cerclage
- Progesterone
- Aspirin
- Arabin Pessary

### **Cervical cerclage**

Cervical cerclage involves the insertion of a surgical suture in the hope of being able to reinforce the mechanical strength of a shortening cervix. This can either be done as an emergency rescue procedure or as a planned prophylactic intervention for a woman with a poor previous obstetric history.

### **Emergency cerclage**

These should only be inserted where a patient presents at <24/40 gestation with a dilated cervix with intact membranes, in the absence of bleeding or contractions. It is crucial to assess maternal well-being through basic observations and measurement of the CRP and white cell

**WAHT-TP-094**

It is the responsibility of every individual to ensure this is the latest version as published on the Trust Intranet

count. Where there is concern over possible sepsis, cerclage should be omitted. Patients should be thoroughly counseled regarding the risks of cerclage (bleeding, rupture of the membranes and subsequent infection) together with the potential that it may not ultimately.

Patients should remain as inpatients following **emergency** cerclage procedure for at least 3 days to watch for the development of sepsis. Four hourly observations and daily white cell counts should be taken following cerclage for three days. Should a patient experience ruptured membranes with a cerclage in situ, the stitch should be removed to minimize the risk of ascending infection on the clear counselling that this may result in preterm labour or late trimester miscarriage.

**Evidence**

The Vaginal Ultrasound Cerclage Trial compared women who had received cervical cerclage with those who had not. Recurrent preterm birth ( $\leq 35$  week's gestation) occurred in 32% of women with a cervical cerclage, compared with 42% of those who did not receive cerclage (OR, 0.67; 95% CI, 0.42–1.07; P 053)<sup>14</sup>. The incidence of preterm birth ( $\leq 35$  weeks gestation) was particularly decreased in the 64 women whose cervical length was less than 15mm at randomization, who subsequently received cerclage. Women with cervical lengths between 15 and 25mm treated with cerclage delivered infants with significantly less morbidity<sup>14</sup>. Historically other studies have found no benefit from cervical cerclage, but this may relate to the previous inability to predict preterm labour and therefore patient mix within the trials. Consequently, cerclage does remain a controversial intervention, although the Royal College of Obstetricians and Gynecologists recommend its use in women with a history of preterm labour and a cervical length of  $< 25\text{mm}$ <sup>8</sup>.

Results from randomized trials show similar rates of preterm birth in women with prior preterm births who undergo a history-indicated, prophylactic cerclage compared with those followed by ultrasound who were treated with cerclage only if the cervix shortened.

Therefore, cervical surveillance using transvaginal scanning can help to select appropriate candidates who would benefit most from cerclage, thus reducing needless surgical intervention and its complications.

Complications of cerclage are not inconsiderable and include infection, risk of bleeding, risk from the anaesthetic and potential increased risk of miscarriage. As such, it is an intervention that should only ever be targeted at those for whom the risk of preterm delivery is significant and in whom the potential for benefit is greatest.

**Progesterone**

**WAHT-TP-094**

It is the responsibility of every individual to ensure this is the latest version as published on the Trust Intranet

There is evidence that vaginal progesterone reduces the risk of recurrent preterm birth<sup>20-22</sup>. In a trial sponsored by The Fetal Medicine Foundation, the overall reduction of preterm birth with vaginal progesterone administered in women with a cervical length of <15mm was 44%<sup>21</sup>. These results have been replicated by others studies<sup>22-23</sup>.

NICE recommend the use of vaginal progesterone in certain situations (see below). This decision should be made following counselling of the woman by a consultant.

- Offer a choice of prophylactic vaginal progesterone or prophylactic cervical cerclage to women who have both:
  - a history of spontaneous preterm birth (up to 34+0 weeks of pregnancy) or mid-trimester loss (from 16+0 weeks of pregnancy onwards) and
  - results from a transvaginal ultrasound scan.... that show a cervical length of 25 mm or less. Discuss the risks and benefits of both options with the woman and make a shared decision on which treatment is most suitable. [2019]
- Consider prophylactic vaginal progesterone (Cyclogest 200mg/PV/nocte) for women who have either:
  - a history of spontaneous preterm birth (up to 34+0 weeks of pregnancy) or mid-trimester loss (from 16+0 weeks of pregnancy onwards) or results from a transvaginal ultrasound scan carried out between 16+0 and 24+0 weeks of pregnancy that show a cervical length of 25 mm or less. [2019]

**Aspirin**

Aspirin is recognized to reduce the risk of pre-eclampsia (16 fewer per 1000 women treated), preterm birth (16 fewer per 1000 treated), the baby being born small-for-gestational age (seven fewer per 1000 treated) and fetal or neonatal death (five fewer per 1000 treated). Overall, administering antiplatelet agents to 1000 women led to 20 fewer pregnancies with serious adverse outcomes.

Aspirin slightly increased the risk of postpartum haemorrhage (>500 mls). Antiplatelet agents marginally increase the risk of placental abruption, but again the quality of the evidence was moderate due to low event numbers and thus wide 95% CI. Overall, aspirin is considered to improve outcome and appears to be safe. See [Aspirin SOP](#).

**Arabin Pessary**


The Arabin pessary is a donut shaped device that sits around the cervix. It has been shown to be beneficial as an alternative to formal cerclage for women with a cervical length <25mm who either decline cerclage or perhaps who present at a gestation which would make cerclage less acceptable. The pessary has been shown to reduce the number of deliveries before 34 weeks of pregnancy (early preterm birth) from 27% in women who did not use the pessary to 6% in those who did. It is inserted much in the same way a pessary is sited for the

**WAHT-TP-094**

It is the responsibility of every individual to ensure this is the latest version as published on the Trust Intranet

management of prolapse and sits around the cervix with the pessary lips pointing away from the cervix to provide additional mechanical strength. The woman should not be aware of it once sited (see diagram below).

**Arabin Pessary**



**Preterm Prevention Clinic (PPC)**

The Preterm Prevention Clinic at Worcester Royal Hospital will see women as soon as possible following booking, at around 14 weeks gestation. These women will have been referred from the community if risk factors for preterm delivery have been highlighted (see below). During this appointment, women would be assessed for clinical risk factors for preterm birth. Depending on the history women may be offered a prophylactic cerclage +/- progesterone supplementation. Women who have had a failed cerclage in the past should be discussed with Birmingham Women’s Hospital.

Transvaginal ultrasound assessment of the cervix will be performed at 16 to 18 week depending on the underlying risk factors. If the cervix is found to be short, i.e. measuring <25mm, the QUiPP app may be used to generate a risk of delivery. Following discussion, the patient may be offered further surgical or medical intervention in the form of cervical cerclage or vaginal progesterone treatment. Women would be seen again at 22 weeks and again at 24 weeks. Women who have undergone screening and have had no intervention may be transferred back into routine care from 24 weeks gestation. Midwifery care is appropriate should there be no further risk factors.

Women who have undergone an intervention e.g. cerclage or progesterone therapy should remain under the Preterm Prevention Clinic until at least 34 weeks.

**WAHT-TP-094**

It is the responsibility of every individual to ensure this is the latest version as published on the Trust Intranet

**Protocol for referral to Preterm Prevention Clinic**

Risk factor	Pathway
<p><b>High risk</b></p> <ul style="list-style-type: none"> <li>• Previous preterm birth or mid-trimester loss (16-34 weeks gestation)</li> <li>• Previous preterm prelabour rupture of membranes (&lt;34/40)</li> <li>• Previous cerclage</li> <li>• Previous trachelectomy</li> <li>• Uterine anomalies (i.e. bicornuate or unicornuate uterus, uterine didelphys)</li> <li>• Ashermanns syndrome</li> </ul>	<p><b>Management</b></p> <ul style="list-style-type: none"> <li>• Review in PPC no later than 16 weeks</li> <li>• Take history</li> <li>• Consider need for history indicated cerclage</li> <li>• Offer transvaginal cervical length scanning 2-4 weekly between 16 and 24 weeks</li> <li>• Use QUIPP to generate risk of delivery if cervix measuring &lt;25mm</li> <li>• Offer intervention as appropriate based on either history or additional screening tests having discussed risks and benefits based on up-to-date guidance from UK Preterm clinical network/NICE.</li> <li>• Interventions may include cervical cerclage, arabin pessary and progesterone.</li> </ul>
<p><b>Intermediate risk</b></p> <ul style="list-style-type: none"> <li>• Previous delivery by LSCS at full dilatation</li> <li>• LLETZ (&gt;10mm depth)</li> <li>• &gt;1 LLETZ performed</li> <li>• Cone biopsy (knife or laser)</li> <li>• Multiple Pregnancy</li> </ul>	<p><b>Management</b></p> <ul style="list-style-type: none"> <li>• Review in PPC no later than 18 weeks</li> <li>• Offer two transvaginal cervical length scans between 18-24 weeks gestation as a minimum</li> <li>• Multiple pregnancy will be offered a single trans vaginal cervical length scan between 16-22 weeks</li> </ul>

## WAHT-TP-094

It is the responsibility of every individual to ensure this is the latest version as published on the Trust Intranet

### General principles

- Consider prophylactic antibiotics if there is a strong history of recurrent UTI.
- Consider a prophylactic cervical suture if there is a history of recurrent late miscarriage or preterm birth, or if there is a history of probable cervical incompetence. Any stitch should be sited as soon as possible following first trimester screening.
- If a prior McDonald's suture has failed, consider Shirodkar and referral to Birmingham/Leeds.
- Consider aspirin (150mg/OD) for women with a history of prior preterm labour or late trimester loss related to PET or placental dysfunction e.g. IUGR. Aspirin is especially important for women with a prior history of placental disease. Women with hepatic or renal disease should have a reduced dose (75mg/OD/PO). Ensure there is no maternal contraindication to taking aspirin.
- Screen all women for asymptomatic bacteriuria through sending MSU for culture and sensitivity at booking. Treat UTI promptly to reduce the risk of subsequent preterm labour. See [MSU SOP](#).
- Undertake HVS at each visit. Treat any infection promptly.
- Pathogens such as *Neisseria Gonorrhoeae* and *Chlamydia Trachomatis* are associated with preterm birth, and screening should be offered to at-risk pregnant women. Healthcare professionals should inform pregnant women under the age of 25 years about the high prevalence of chlamydial infection in their age group and offer screening using NAAT swab.
- Ensure that women are asked about domestic violence via the routine enquiry and document in the notes. Where necessary alert safeguarding midwife and offer additional support.
- Do not give steroids if the QUIPP risk is > 5%
- If the cervix is <25mm with recall to clinic in 1 week for a repeat ultrasound
- Aim to remove cervical suture or arabin pessary pre-labour at 36-37/40
- **Remove cervical suture or arabin pessary if SRROM or signs of labour**

**WAHT-TP-094**

It is the responsibility of every individual to ensure this is the latest version as published on the Trust Intranet

- If women present with potential preterm labour, please refer to the WAHT Management of preterm labour guideline and ensure the appropriate administration of steroids, tocolysis and magnesium per protocol.
- Use the QuIPP APP, with the cervical length to generate the risk of delivery.
- Counsel the patient regarding the risk of delivery over the next 1 week, 2 weeks and 4 weeks and document in notes.

**High Vaginal Swab**

As part of their care under the PPC, women will require High vaginal swabs (HVS) for analysis. Women need to have a speculum examination in order to have a HVS taken and where possible, this will be done in Antenatal Clinic or within the PPC. However, there will be times when women will need to attend other departments such as EPAU, Triage or Day Assessment Unit. The gestational age of these women will range from approximately 12 weeks up to term.

If the woman is asymptomatic, competent midwives and nurses can perform the speculum examination for the purpose of taking the HVS only. This is not an examination to visualise the cervix, the speculum is just to facilitate the HVS being taken correctly.

If the woman is symptomatic and is complaining of any pain, fluid loss, bleeding or any other concerns that they would seek medical review for, the woman should be referred for the appropriate medical review.

The reason for the HVS request will be clearly documented on the women’s electronic notes and the appropriate departments will be notified in advance where possible.

**QuIPP**

The QUIPP app is a clinical decision-making tool with the potential to revolutionize preterm birth prediction for women with symptoms of threatened preterm labour as well as asymptomatic high-risk women. Accurate diagnosis of preterm labour is desirable in order to prevent the maternal and fetal risks incurred by the majority of women who are over-managed, without missing true cases.

The QuIPP application has been designed for health, allied health and health research professionals who look after pregnant women to calculate individualised percentage risks scores for delivery, within pre-specified clinically relevant timeframes. It is designed to be used with women as an educational tool and to arrive at shared decisions regarding the management of their pregnancy.

It is designed for use in two clinical settings:

**WAHT-TP-094**

It is the responsibility of every individual to ensure this is the latest version as published on the Trust Intranet

1. For management of asymptomatic women at high-risk for preterm birth (delivery before 37 weeks' gestation) who are attending preterm surveillance clinics
2. For management of women with symptoms suggestive of abnormal or premature uterine activity (e.g. abdominal pain, contractions, tightenings).

It relies on a relevant clinical history having been taken regarding the woman's risk factors for preterm birth and her current symptoms. It relies on existing point-of-care testing: quantitative fetal fibronectin (fFN) sampling of the cervico-vaginal fluid and/or transvaginal ultrasound cervical length (CL) measurements. Therefore, the user is expected to have significant midwifery or obstetric experience to use QUIPP app or is working closely with a team-member who does.

**How to counsel**

Using a 5% risk of delivery within 7 days according to the QUIPP App as the threshold for intervention, 9/9 women with threatened preterm labour would have been treated correctly, giving a sensitivity of 100% (97.5% CI, 66.4%) and a negative predictive value of 100% (95% CI, 98.9–100% ). The positive predictive value for delivery within 7 days was 30.0% (95% CI, 11.9–54.3%) for women presenting before 30 weeks and 20.0% (95% CI, 4.3–49.1%) for women presenting between 30 and 34 weeks. If this 5% threshold had been used to triage women presenting between 24 and 29+6 weeks, 89.4% (n=168) of admissions could have been safely avoided, compared with 0% for a treat-all strategy. No true case of preterm labour would have been missed, as no woman who was assigned a risk of <10% delivered within 7 days.

For women with threatened preterm labour, the QUIPP App can accurately guide management at risk thresholds for sPTB of 1%, 5% and 10%, allowing outpatient management in the vast majority of cases. A treat-all approach would not have avoided admission for any woman, exposed 188 mothers and their babies to unnecessary hospitalization and steroid administration and increased the burden on network and transport services owing to unnecessary in-utero transfers. Prediction of sPTB should be performed before 30 weeks to determine management until there is evidence that such a high level of unnecessary intervention, as suggested by the treat-all strategy, does less harm than the occurrence of rare false negatives.

## References

1. Slattery MM, Morrison JJ. Preterm delivery. *Lancet* 2002; 360:1489–1497
2. Maternal and Child Health Consortium. 6th Annual Report: Confidential Enquiries into Stillbirths and Deaths in Infancy (CESDI). London: HMSO; 1999
3. Yuan W, Duffner AM, Chen L, *et al.* Analysis of preterm deliveries below 35 weeks' gestation in a tertiary referral hospital in the UK. A case-control survey. *BMC Res Notes* 2010;3:119.
4. Shennan AH, Bewley S. Why should preterm births be rising? *BMJ* 2006;332:924-925
5. Goffinet F. Primary predictors of preterm labour. *BJOG* 2005; 112 (S1): \_38–47
6. Burnett AF. Radical trachelectomy with laparoscopic lymphadenectomy: review of oncologic and obstetrical outcomes. *Curr Opin Obstet Gynecol* 2006 18:8–13
7. Honest H, Khan KS. Preterm birth. In: Critchley H, Bennett P, Thornton S, editors. *Preterm labour and the cervicovaginal fetal fibronectin test*. London: RCOG Press; 2004. pp. 181–187.
8. RCOG Greentop Guideline on Cervical Cerclage
9. Berghella. V, Hayes. E, Vistine.J, Baxter.JK. Fetal Fibronectin testing for reducing the risk of preterm birth. *Cochrane Review* 2008
10. Shennan A, Jones G, Hawken J, *et al.* Fetal fibronectin test predicts delivery before 30 weeks of gestation in high-risk women but increases anxiety. *BJOG* 2005; 112:293–298
11. Romero R, Espinoza J, Mazor M, Chaiworapongsa T. The preterm parturition syndrome. In: Critchley H, Bennett P, Thornton S, editors. *Preterm Birth*. London: RCOG Press; 2004. pp. 28–60.
12. Iams JD, Goldenberg RL, Mercer BM, *et al.* The preterm prediction study: recurrence risk of spontaneous PTB. *Am J Obstet Gynecol* 1998;178:1035-40.
13. Abbott DS, Radford SK, Seed PT *et al.* Evaluation of a quantitative fetal fibronectin test for spontaneous preterm birth in symptomatic women. *Am J Obstet Gynecol* 2013;208:122,e1-6
14. Owen J, Hankins G, Iams JD, *et al.* multi-center randomized trial of cerclage for prevention of preterm birth in high-risk women with shortened mid-trimester cervical length. *Am J Obstet Gynecol* 2009;201:375.e1-8
15. Meis PJ, Klebanoff M, Thom E, *et al.* Prevention of recurrent preterm delivery by 17- alpha-hydroxyprogesterone caproate. *N Engl J Med* 2003;348:2379-85
16. Spong CY, Meis PJ, Thom EA, *et al.* Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. *Am J Obstet Gynecol* 2005;193: 1127-31.

**WAHT-TP-094**


It is the responsibility of every individual to ensure this is the latest version as published on the Trust Intranet

17. Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17-alpha-hydroxyprogesterone caproate. *N Engl J Med* 2003;348:2379-85
18. Meis PJ; Society for Maternal-Fetal Medicine. 17 Hydroxyprogesterone for the prevention of preterm delivery. *Obstet Gynecol* 2005;105(5 Pt 1):1128-35.
19. Dodd JM, Flenady V, Cincotta R, Crowther CA. Prenatal administration of progesterone for preventing PTB. *Cochrane Database Syst Rev* 2006;1:CD004947
20. Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous PTB in women at increased risk: a randomized placebo-controlled double-blind study. *Am J Obstet Gynecol* 2003;188:419-24.
21. Fonseca EB, Celik E, Parra M et al. Progesterone and the risk of preterm birth among women with a short cervix. *N Engl J Med* 2007;.357:462-9
22. Hassan SS, Romero R, Vidyadhari D, Fusey S, Baxter JK, Khandelwal M, et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. *Ultrasound Obstet Gynecol* 2011;38:18–31.
23. Romero R, Nicolaides K, Conde-Agudelo A, Tabor A, O'Brien JM, Cetingoz E, et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the mid-trimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. *Am J Obstet Gynecol* 2012;206:124 e1–e19.
24. Farine D, Mundle WR, Dodd J, Basso M, Delisle MF, Grabowska K; Maternal Fetal Medicine Committee of the Society of Obstetricians and Gynaecologists of Canada. The use of progesterone for prevention of preterm birth. SOGC technical update, No. 202, January 2008. *J Obstet Gynaecol Can* 2008;30:67–71.
25. Preventing Preterm Birth: The Role of 17 $\alpha$ -Hydroxyprogesterone Caproate. Albany, N.Y: American College of Obstetricians and Gynecologists; Jan, 2009
26. Antiplatelet agents for preventing pre-eclampsia and its complications - Cochrane Review
27. Saving Babies Lives Bundle Version 2
28. The QUIPP App: a safe alternative to a treat-all strategy for threatened preterm labour. H. A. WATSON, J. CARTER, P. T. SEED, R. M. TRIBE and A. H. SHENNAN *Ultrasound Obstet Gynecol*. 2017 Sep;50(3):342-346. doi: 10.1002/uog.17499. Epub 2017 Jul 30.
29. Watson HA<sup>1</sup>, Carter J<sup>1</sup>, David AL<sup>2</sup>, Seed PT<sup>1</sup>, Shennan AH<sup>1</sup>. **Full dilation cesarean section: a risk factor for recurrent second-trimester loss and preterm birth.** *Acta Obstet Gynecol Scand*. 2017 Sep;96(9):1100-1105. doi: 10.1111/aogs.13160. Epub 2017 Jun 8.
30. Berghella V, Gimovsky AC, Levine LD, Vink J, Cesarean in the second stage: a possible risk factor for subsequent spontaneous preterm birth *American Journal of Obstetrics & Gynecology* JULY 2017

**WAHT-TP-094**

It is the responsibility of every individual to ensure this is the latest version as published on the Trust Intranet

**Flow chart for Preterm Prevention Clinic**



**WAHT-TP-094**

It is the responsibility of every individual to ensure this is the latest version as published on the Trust Intranet

**Monitoring**

Page/ Section of Key Document	Key control:	Checks to be carried out to confirm compliance with the Policy:	How often the check will be carried out:	Responsible for carrying out the check:	Results of check reported to: <i>(Responsible for also ensuring actions are developed to address any areas of non-compliance)</i>	Frequency of reporting:
	<b>WHAT?</b>	<b>HOW?</b>	<b>WHEN?</b>	<b>WHO?</b>	<b>WHERE?</b>	<b>WHEN?</b>
	Saving Babies Lives Element 5 Audits	Audits	Quarterly	SBL Midwife	Maternity Governance/ LMNS/ ICB	Quarterly

**WAHT-TP-094**

It is the responsibility of every individual to ensure this is the latest version as published on the Trust Intranet

**Contribution List**

This key document has been circulated to the following individuals for consultation;

Designation
Maternity Governance Meeting

This key document has been circulated to the chair(s) of the following committee's / groups for comments;

Committee
Maternity Quality Governance Meeting